Você está na página 1de 23

Foreign

Pharmacy
Graduate
Equivalency
Examination®
(FPGEE®)

Study Guide
FPGEE Study Guide

©2007 by the National Association of Boards of Pharmacy. All rights reserved.

No part of this publication may be reproduced in any manner without the written permission of the Executive
Director/Secretary of the National Association of Boards of Pharmacy. Violation of the copyright will lead to
prosecution under federal copyright laws.

National Association of Boards of Pharmacy reg. no. 1,162,334


NABP reg. no. 1,160,482
Foreign Pharmacy Graduate Equivalency Examination reg. no. 2,270,607
FPGEC reg. no. 2,113,836
FPGEE reg. no. 2,337,295

National Association of Boards of Pharmacy


Foreign Pharmacy Graduate Examination Committee
1600 Feehanville Drive
Mount Prospect, IL 60056
USA
847/391-4406
www.nabp.net

Carmen A. Catizone, MS, RPh, DPh


Executive Director/Secretary
1/07
Table of
Contents
FPGEE Blueprint............................................................................... 1
Sample Questions............................................................................... 7
Answer Key....................................................................................... 13
Textbooks Commonly Used in US Pharmacy Schools.................. 15
FPGEE Blueprint

FPGEE Administration d. Developmental defects


The Foreign Pharmacy Graduate Equivalency e. Neoplasia
Examination® (FPGEE®) is based on a nationally 2. Pathophysiology of disease states
uniform content blueprint. The following blueprint, amenable to pharmacist intervention
revised in 2007, provides important information C. Microbiology
about the topics covered on the examination and the 1. General principles of microbial concepts
knowledge you are expected to demonstrate while
2. Principles of infectious disease
taking the FPGEE.
The examination is a comprehensive measure of 3. Host-parasite relationships
knowledge in four major pharmacy content areas: 4. Pathogenic micro-organisms of man
21% – Basic Biomedical Sciences 5. Inflammatory responses to infectious
29% – Pharmaceutical Sciences agents
15% – Social/Behavioral/Administrative 6. Clinical aspects of infection
Pharmacy Sciences D. Immunology
35% – Clinical Sciences 1. Human immunity and immune responses
You must take the examination at one of two 2. Principles of antigen-antibody
consecutive opportunities upon being accepted to relationships
take the FPGEE. Additional opportunities to take 3. Molecular biology of immune responses
the FPGEE will only be allowed if NABP receives
4. Genetic basis for antibody synthesis,
an official denial of your visa or you have a health
development, function and
or work-related problem that is substantiated on
immunopathology
official stationary from your health provider or place
of employment stating that you can not attend your E. Biochemistry/Biotechnology
second or subsequent opportunity. 1. Chemistry of biomacromolecules
A strong understanding of the following (proteins, lipids, carbohydrates, and
blueprint will aid in your preparation to take the DNA)
examination. 2. Enzymology and co-enzymes and
kinetics
Area 1 – Basic Biomedical Sciences – 21% 3. Metabolic pathways to energy utilization

FPGEE Blueprint
A. Anatomy & Physiology 4. Nucleic acid metabolism including DNA
1. Structure and function of major body replication and repair, RNA and protein
systems; integumentary, muscular synthesis
skeletal, cardiovascular, lymphatic, 5. Recombinant DNA technology
respiratory, digestive, nervous, endocrine,
F. Molecular Biology/Genetics
urinary, reproductive and body fluid and
electrolytes 1. Cell structure and components
2. Molecular aspects of cell biology 2. Ion channels and receptor physiology
3. Cell physiology and cellular structure and 3. Mitosis and meiosis
organization 4. Chromosomes and DNA
B. Pathology/Pathophysiology 5. Gene transcription and translation
1. Basic principles and mechanisms of processes
disease including: 6. Recombinant DNA technology
a. Inflammation and repair G. Biostatistics
b. Degeneration 1. Understanding commonly used statistical
c. Disturbances and hemodynamics tests and their basis

1
2. Management of data sets 3. Interpretation of drug screens
3. Evaluation of statistical results 4. Antidotes and approaches to toxic exposures
4. Understanding of statistical versus clinical 5. Functions of poison control centers
significance 6. Bioterrorism and disaster preparedness and
Area 2 – Pharmaceutical Sciences – 29% management
A. Medicinal Chemistry E. Bioanalysis/Clinical Chemistry
1. Physio-chemical properties of drug molecules 1. Fundamentals of laboratory medicine and
in relation to drug absorption, distribution, its importance to screening, diagnosis, and
metabolism, and excretion (ADME) evaluation of patients
2. Chemical basis and pharmacology and 2. Clinical data relevant to disease state
therapeutics management
3. Fundamental pharmacophores for drugs used F. Pharmaceutics/Biopharmaceutics
to treat disease 1. Physical-chemical principles of dosage forms
4. Structure activity relationships in relation to 2. Biological principles of dosage forms
drug-target interactions 3. Principles of drug delivery via dosage forms
5. Chemical pathways of drug metabolism (eg, liquid, solid, semi-solid, controlled
6. Application to making drug therapy decisions release, patches, and implants)
B. Pharmacology 4. Principles of dosage form stability and drug
1. Mechanism of action of drugs of various degradation in dosage forms
categories 5. Materials and methods used in preparation
2. Role of pharmacology in drug choice and the and use of drug forms
treatment of disease G. Pharmacokinetics/Clinical Pharmacokinetics
3. Pharmacodynamics of drug action and 1. Basic principles of in vivo drug kinetics
absorption, distribution, metabolism, and (linear and nonlinear)
elimination 2. Principles of bioavailability/bioequivalence
4. Adverse effects and side-effects of drugs 3. Physiologic determinates of drug onset and
5. Drug-target interactions duration
6. Drug-drug, drug-food, drug-lab test interactions 4. Drug, disease, and dietary influences on
7. Drug discovery and development absorption, distribution, metabolism, and
C. Pharmacognosy and Alternative and excretion
Complementary Treatments 5. Clinical pharmacokinetics of commonly used
1. Concepts of crude drugs, semi-purified, and and low-therapeutic-index drugs
purified natural products 6. The pharmacokinetic-pharmacodynamic
2. Variability of occurrence of interface
pharmacologically active substances in plants H. Pharmacogenomics/Genetics
and impact on regulatory aspects of herbal 1. Genetic basis for disease and drug action
products 2. Genetic basis for alteration and drug
3. Overview of classes of pharmacologically metabolism
active natural products 3. Genome and proteomic principles in relation
4. Dietary supplements (vitamins, minerals, and to disease and drug development
herbals) 4. Genetic basis for individualizing drug doses
5. Alternative medical treatments I. Extemporaneous Compounding/Parenteral/Enteral
6. Evaluation of alternative and complementary 1. United States Pharmacopeia (USP) guidance
medicine purity, bioavailability, safety, and on compounding and Food and Drug
efficacy Administration (FDA) Compliance Policy
7. Herbal-drug interactions Guidelines
8. Dietary Health Supplement and Education 2. Techniques and principles used to prepare
Act and impact on regulation of dietary and dispense individual extemporaneous
supplements and herbal products prescriptions including dating of compounded
D. Toxicology dosage forms
1. Mechanism of toxicity and toxicokinetics 3. Liquid (parenteral, enteral), solid, semi-solid,
2. Acute and chronic toxic effect of xenobiotics and topical preparations
on the body including drug or chemical 4. Dosage form preparation calculations
overdose and toxic signs of drugs of abuse 5. Sterile admixture techniques

2
a. USP Chapter 797 8. Basic accounting principles
b. Stability and sterility testing and dating 9. Infection control
c. Clean room requirements 10. Project management
d. Infusion devices and catheters 11. Managing and improving the medication-
Area 3 – Social/Behavioral/Administrative use process
Pharmacy Sciences – 15% 12. Third-party administration and managed
A. Health Care Delivery Systems care systems
1. Introduction to United States, state, and 13. Health care improvement mechanisms at
local health care delivery systems and the micro- and macro-system levels
their interfaces D. Pharmacoepidemiology
2. Social, political, and economic factors of 1. Application of principles of
the US health care delivery system epidemiology to the study of drug use
3. Principles that influence the distribution and outcomes in large populations
of pharmaceutical products and services 2. Studies that provide an estimate of
4. Role of public and private insurers, the probability of beneficial effects
pharmaceutical industry, and managed in populations, or the probability of
care on health care delivery in the United adverse effects in populations, and other
States parameters relating to drug use may
5. Medicare and Medicaid benefit
6. Indigent care programs 3. Methods for continual monitoring for
7. Incidence of and problems associated unwanted effects and other safety-related
with drug overuse, underuse, and misuse aspects of drugs
in the US health care system E. Pharmacy Law and Regulatory Affairs
B. Economics/Pharmacoeconomics 1. Legal basis for pharmacy practice
1. Economic principles in relation to 2. Pharmacist’s responsibilities and limits
pharmacoeconomic analysis under the law
2. Concepts of pharmacoeconomics in 3. Pharmacist’s role in reducing liability by
relation to patient care reducing drug-related misadventure
3. Applications of economic theories and 4. Civil versus criminal liability
health-related quality-of-life concepts to 5. Business contract law
improve allocation of limited health care F. History of Pharmacy
resources 1. Overview of the evolution of pharmacy
C. Practice Management as a distinct profession
1. Management principles (planning, 2. Moving from focus on the drug to focus
organizing, directing, and controlling on the patient and the drug, including
pharmacy resources) applied to various clinical, pharmaceutical care and other
pharmacy practice setting and patient aspects of patient-provided pharmacist
outcomes care
2. Management of staff within the 3. Major milestones and contributors in the

FPGEE Blueprint
practice setting including pharmacists, evolution of pharmacy
technicians, and other supportive G. Ethics
personnel 1. Principles of professional behavior
3. Principles of planning, organizing, 2. Ethical issues related to the development,
directing, and controlling pharmacy promotion, sales, prescription, and use of
resources drugs
4. Tools, including informatics, needed 3. Dealing with ethical dilemmas
to assess and address change, increase 4. Conflict of interest
competitiveness, improve quality, and
5. Ethical issues in delivery of patient-
optimize patient services
centered care and clinical research
5. Management of medication use safety
6. Principles of end-of-life care
systems
7. Ethical issues in teamwork
6. Strategies to improve continuity of
patient care as patients move between H. Professional Communications
health care settings 1. Effective verbal and written interpersonal
7. Marketing principles communication
2. Health literacy

3
3. Communicating with diverse patients, 5. Issues of distribution systems associated with
families, pharmacists, and other health all types of practice settings
professionals in a variety of settings both 6. Role of automation and technology in
individually and as a member of a team workload efficiency and patient safety
4. Interviewing techniques 7. Assurance of safety in the medication-use
5. Active listening and empathy process
6. Assertiveness and problem-solving 8. Medication error reduction programs
techniques 9. Continuous quality improvement programs
7. Cultural influences on communication of C. Pharmacotherapy – Practice Guidelines and
health information Clinical Trials
8. Group presentation skills 1. Principles of clinical practice guidelines for
9. Strategies for handling difficult situations various disease states and their interpretation
10. Documentation of pharmacist in the clinical setting
recommendations and consultations 2. Integration of core scientific and systems-
11. Principles of behavior modification based knowledge in patient care decisions
I. Social and Behavioral Aspects of Practice 3. Reinforcement of basic science principles
1. Pharmacy as a patient-centered profession relative to drug treatment protocols and
2. Patient and other health care providers clinical practice guidelines
perceptions of pharmacists’ capabilities 4. Evaluation of clinical trials that validate
3. Role of pharmacist related to patient care treatment usefulness
4. Role of pharmacist related to interaction with D. Pharmacotherapy – Health Promotion/Disease
other health care professionals Prevention
5. Development of leadership skills 1. Promotion of wellness and nonpharmacologic
therapies
6. Importance of involvement in pharmacy
organizational, regulatory, state, and federal 2. Disease prevention and monitoring
issues E. Pharmacotherapy – Pharmaceutical Care
Area 4 – Clinical Sciences – 35% 1. Application of evidence-based decision
A. Pharmacy Practice and Pharmacist-Provided Care making to patient care
1. Overview of the pharmacy profession 2. Drug monitoring for positive and negative
outcomes
2. Issues of contemporary practice
3. Diagnostic tests in the diagnosis, staging, and
3. Emerging and unique roles for the pharmacist
monitoring of various disease states
on the health care team
4. Concepts of pain management and palliative
4. Concepts of pharmacist-provided patient care
care
and medication therapy management services
5. Nonprescription drug therapies
5. Principles of pharmacist-managed, patient-
centered pharmacy services 6. Dietary drug therapies
6. Methods of outcome monitoring and 7. Designing of patient-centered, culturally
assessment techniques relevant treatment plans
7. Problem identification (eg, duplication, 8. Drug-induced disease
dosage, drug interactions, adverse drug F. Pharmacist-provided Care for Special Populations
reactions and interactions, frequency, dosage 1. Pathophysiologic and pharmacotherapy
form, indication mismatches) and resolution alterations specific for special population
8. Role of pharmacy care plans in patient care patients (eg, pediatric, geriatric, pregnant,
9. Monitoring for positive and negative drug cystic fibrosis, sickle cell anemia, celiac
therapy outcomes disease, genetic disorders, and others) for
prescription and nonprescription medications
10. Principles of clinical management of drug
toxicity and overdosage 2. Dosage calculation and adjustment in special-
population patients
11. Home diagnostic devices
3. Drug monitoring for positive/negative
B. Medication Dispensing and Distribution Systems
outcomes in special-population patients
1. Preparation and dispensing of prescriptions
G. Drug Information
2. Development and maintenance of patient
1. Fundamentals of the practice of drug information
medication profiles
2. Application of drug information skills for
3. Identification and prevention of medication
delivery of pharmaceutical care
errors
4. Identification and prevention of drug toxicity

4
3. Technology of drug information retrieval 1. Obtaining a comprehensive patient
for quality assurance history
4. The ability to judge the reliability of 2. Familiarity with basic assessment
various sources of information techniques (inspection, palpation,
H. Medication Safety percussion, auscultation), terminology,
1. Causes of medication errors/systems and the modifications caused by common
approaches disease states and drug therapy
2. Human factors in errors 3. Triage and referral skills
3. Strategies for reducing errors 4. Knowledge of therapeutic drug
concentrations and their interpretation
4. Pharmacy leadership in medication safety
5. Knowledge of the basis for common
I. Literature Evaluation and Research Design
clinical laboratory values and diagnostic
1. Fundamentals of research design and tests and the influences of common
methodology disease states
2. Principles of evaluation of the primary 6. False positive and false negative results
literature
7. Over-the-counter point-of-care testing
3. Practical implications of the primary devices (eg, glucometers, pregnancy
literature tests, home testing for HbA1c, drug
4. Principles of research design and analysis screening)
in practicing evidence-based pharmacy 8. Principles of electrocardiography and
J. Patient Assessment Laboratory common EKG abnormalities
9. Advanced cardiac life support

FPGEE Blueprint

5
6
Sample Questions

Sample Questions

7
8
Sample Questions

9
10
Sample Questions

11
12
Answer Key

Area I Area III


1 C 21 B
2 D 22 C
3 A 23 A
4 A 24 A
5 A 25 B
6 D 26 A
7 D
8 D
Area IV
27 C
Area II 28 A
9 D 29 B
10 D 30 C
11 D 31 C
12 D 32 C
13 B 33 B
14 B 34 B
15 C 35 B
16 A 36 A
17 C 37 C
18 B 38 A
19 A 39 B
20 B 40 B

Answer Key

13
14
Textbooks Commonly Used in
US Pharmacy Schools

The following is a suggested reading list. It does not Cipolle RJ, Strand LM, Morley PC. Pharmaceutical
claim to include all textbooks used in US pharmacy Care Practice: The Clinicians Guide. 2nd ed.
schools but is a guide for your preparation. Many of the McGraw-Hill Medical; 2004.
books on this list have been published in more than one
Connors KA, Amidon GL, Stella VJ. Chemical
edition. Please consult a bookstore or a health sciences
Stability of Pharmaceuticals: A Handbook for
librarian for more detailed information.
Pharmacists. 2nd ed. Wiley-Interscience; 1986.
Anderson PO. Handbook of Clinical Drug Data. 10th Conway TW, Spector AA, Chappell D, Montgomery
ed. McGraw-Hill Medical; 2001. R (Ed). Biochemistry: A Case-Oriented Approach.
6th ed. C.V. Mosby; 1996.
Ansel HC, Allen LV, Popovich NG. Pharmaceutical
Dosage Forms and Drug Delivery Systems. 8th ed. Delvin TM. Textbook of Biochemistry with Clinical
Lippincott Williams & Wilkins; 2004. Correlations. 6th ed. Wiley-Liss; 2006.
Ansel HC, Stoklosa MJ. Pharmaceutical Calculations. Dennerll JT, Davis PE. Medical Terminology: A
12th ed. Lippincott Williams & Wilkins; 2006. Programmed Systems Approach. 9th ed, Thomson
Delmar Learning; 2004.
Banker GS, Rhodes CT, Eds. Modern Pharmaceutics,
Drugs & the Pharmaceutical Sciences. 4th ed. DiPiro JT, Talbert RL, Yee GC, et al.
Marcel Dekker; 2004 Pharmacotherapy: A Pathophysiologic Approach.
6th ed. McGraw-Hill Medical; 2005.
Berardi RR, Kroon L, McDermott J, et al. Handbook
of Nonprescription Drugs. 15th ed. APhA Fink JL. Pharmacy Law Digest, 2006: The Definitive
Publications; 2006. Source of Pharmacy Law. 40th ed. Facts and
Comparisons; 2005.
Berg JM, Stryer L, Tymoczko JL. Biochemistry. 5th ed.
W.H. Freeman ; 2002. Ganong WF. Review of Medical Physiology. 22nd ed.
McGraw-Hill Medical; 2005.
Block J, Wilson CO, Beale JM, Gisvold O, Eds.
Wilson and Gisvold’s Textbook of Organic Gilbert DN, Moellering RC, Eliopoulos GM, Sande
Medicinal and Pharmaceutical Chemistry. 11th ed. MA. The Sanford Guide to Antimicrobial Therapy,
Lippincott Williams and Wilkins; 2004. 2005. 35th ed. Antimicrobial Therapy, Inc; 2005.
Bodenheimer T, Grumbach K. Understanding Health Gossel TA, Bricker JD. Principles of Clinical
Policy: A Clinical Approach. 4th ed. McGraw-Hill Toxicology. 3rd ed. CRC Press; 1994.
2005. Katzung BG. Basic & Clinical Pharmacology. 9th ed.
in US Pharmacy Schools
Textbooks Commonly Used
Bootman JL, Townsend RJ, McGhan WF, Eds. McGraw-Hill Medical; 2003.
Principles of Pharmacoeconomics. 3rd ed. Harvey Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo
Whitney Books Company, 2004. BJ, Alldredge BK, Corelli RL, Eds. Applied
Borgsdorf LR, Selevan JR, Cada DJ, (Eds), et al. Drug Therapeutics: The Clinical Use of Drugs. 8th ed.
Facts and Comparisons 60th Ed. 2006. Lippencott Lippencott Williams & Wilkins; 2004.
Williams & Wilkins; 2004 Kumar V, Fausto N, Abbus A. Robbins & Cotran
Brunton L, Lazo J, Parker K. Goodman and Gilman’s Pathologic Basis of Disease. 7th ed. W.B. Saunders
The Pharmacological Basis of Therapeutics. 11th Company; 2004.
ed. McGraw-Hill Professional; 2005. Lemke TL. Review of Organic Functional Groups:
Carstensen JT. Pharmaceutical Principles of Solid Introduction to Medicinal Organic Chemistry. 4th
Dosage Forms. CRC Press; 1993. ed. Lippincott Williams & Wilkins; 2003.

15
McCarthy R, Schafermeyer K. Introduction to Health Care Tarto DS, Ed. Drug Interaction Facts 2007: The authority
Delivery: A Primer for Pharmacists. 3rd ed. Jones and on drug interactions. Lippencott Williams & Wilkins;
Bartlett 2004. 2006.
Murphy JE. Clinical Pharmacokinetics – Pocket Thompson J. A Practical Guide to Contemporary
Reference. 3rd ed. American Society of Health-System Pharmacy Practice. 2nd ed. Lippincott Williams and
Pharmacists; 2004. Wilkins 2004.
Nelson DL, Cox MM. Lehninger’s Principles of Tindall WN, Beardsley RS, Kimberlin CL, Eds.
Biochemistry. 4th ed. W.H. Freeman; 2004. Communication Skills in Pharmacy Practice: A
Rhodes CT, Carstensen JT, Eds. Drug Stability: Principles Practical Guide for Students and Practitioners. 4th ed.
and Practice. 3rd ed. Marcel Dekker; 2000. Lippencott Williams & Wilkins; 2002.
Ritschel WA, Kearns GL. Handbook of Basic Tinoco I, Sauer K, Wang JC, Puglisi JD. Physical
Pharmacokinetics. 6th ed. APhA Publications; 2004. Chemistry: Principles & Applications in Biological
Sciences. 4th ed. Prentice Hall; 2001.
Rowland M, Tozer TN. Clinical Pharmacokinetics. 3rd ed.
Lippencott Williams & Wilkins; 1995. Troy DB, Ed. Remington: The Science and Practice of
Pharmacy. 21st ed. Lippincott Williams & Wilkins;
Shargel L, Wu-Pong S, Yu AB. Applied Biopharmaceutics 2005.
and Pharmacokinetics. 5th ed. McGraw-Hill Medical;
2004. USPDI Volumes 1, II, & III. 26th ed. Thomson Micromedex;
2006.
Shaw LM, Schentag JJ, Evans WE, Burton ME (Ed).
Applied Pharmacokinetics: Principles of Therapeutic Williams DA, Lemke TL, Foye WO. Foye’s Principles of
Drug Monitoring. 4th ed. Lippencott Williams & Medicinal Chemistry. 5th ed. Lippincott Williams and
Wilkins; 2005. Wilkins; 2002.
Shi L, Singh D. Delivering Health Care in America. 3rd ed. Winter ME. Basic Clinical Pharmacokinetics. 4th Edition.
Jones and Barlett; 2004. Lippencott Williams & Wilkins; 2003.
Sinko P. Martin’s Physical Pharmacy and Pharmaceutical Zatz JL, Teixeira MG. Pharmaceutical Calculations. 4th ed.
Sciences. Lippincott Williams and Wilkins; 2005 Wiley-Interscience; 2005.
Smith MC, Kolassa EM, Perkins B, Seicker G, Eds.
Pharmaceutical Marketing: Principles, Environment
and Practice. Haworth Press; 2001

16
17
Preamble and Mission Statement of the
National Association of Boards of Pharmacy
Preamble
Given that medications are an integral part of disease management, medication therapies and their delivery systems
are becoming more complex, technological enhancements have improved the capabilities for patient monitoring, and
entities motivated by economic gain are eroding standards of care, there is greater potential harm to the public and
a greater need for patients’ medication use to be managed by a licensed pharmacist and state regulatory agencies to
aggressively enforce standards of care.

NABP Mission Statement


The National Association of Boards of Pharmacy (NABP) is the independent, international, and impartial
Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform
standards for the purpose of protecting the public health.

NABP Member Boards of Pharmacy


Alabama State Board of Pharmacy Michigan Board of Pharmacy Virgin Islands Board of Pharmacy
Alaska Board of Pharmacy Minnesota Board of Pharmacy Virginia Board of Pharmacy
Arizona State Board of Pharmacy Mississippi Board of Pharmacy Washington State Board of Pharmacy
Arkansas State Board of Pharmacy Missouri Board of Pharmacy West Virginia Board of Pharmacy
California State Board of Pharmacy Montana Board of Pharmacy Wisconsin Pharmacy Examining Board
Colorado State Board of Pharmacy Nebraska Board of Pharmacy Wyoming State Board of Pharmacy
Connecticut Commission of Pharmacy Nevada State Board of Pharmacy Australia:
Delaware State Board of Pharmacy New Hampshire Board of Pharmacy Pharmacy Board of New South Wales*
District of Columbia Board of Pharmacy New Jersey Board of Pharmacy Pharmacy Board of Victoria*
Florida Board of Pharmacy New Mexico Board of Pharmacy Canada:
Georgia State Board of Pharmacy New York State Board of Pharmacy Alberta College of Pharmacists*
Guam Board of Examiners for Pharmacy North Carolina Board of Pharmacy College of Pharmacists of British
Hawaii State Board of Pharmacy North Dakota State Board of Pharmacy Columbia*

Idaho Board of Pharmacy Ohio State Board of Pharmacy Manitoba Pharmaceutical Association*

Illinois Department of Financial and Oklahoma State Board of Pharmacy New Brunswick Pharmaceutical
Professional Regulation, Division of Oregon State Board of Pharmacy Society*
Professional Regulation – State Board Nova Scotia College of Pharmacists*
of Pharmacy Pennsylvania State Board of Pharmacy
Puerto Rico Board of Pharmacy Ontario College of Pharmacists*
Indiana Board of Pharmacy
Rhode Island Board of Pharmacy Prince Edward Island Pharmacy
Iowa Board of Pharmacy Board*
Kansas State Board of Pharmacy South Carolina Department of Labor,
Licensing, and Regulation – Board of Quebec Order of Pharmacists*
Kentucky Board of Pharmacy Pharmacy New Zealand:
Louisiana Board of Pharmacy South Dakota State Board of Pharmacy Pharmacy Council of New Zealand*
Maine Board of Pharmacy Tennessee Board of Pharmacy Africa:
Maryland Board of Pharmacy Texas State Board of Pharmacy South African Pharmacy Council*
Massachusetts Board of Registration Utah Board of Pharmacy
in Pharmacy * Associate Member
Vermont Board of Pharmacy

18
National Association of Boards of Pharmacy
1600 Feehanville Drive
Mount Prospect, IL 60056
847/391-4406
www.nabp.net

19

Você também pode gostar